Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHwan LeeJSJakub SvobodaCDChristopher R. D’Angelo

Discussion

Loading...

Member takes

Overview

Phase IIa trial shows bispecific antibodies enhance CAR-T expansion in relapsed large B-cell lymphomas, indicating improved clinical outcomes.

Key Points

  • To evaluate the safety and efficacy of early administration of bispecific antibodies after CAR-T therapy.
  • Phase IIa multi-center clinical trial
  • Patients with relapsed/refractory large B-cell lymphomas receiving CAR-T
  • Bispecific antibodies administered 31-45 days post CAR-T infusion
  • Assessment of response and CAR-T expansion in blood
  • CR rate at 24 weeks indicated potential efficacy of bispecific antibodies
  • Neutropenia occurred in one mosunetuzumab patient
  • Cytokine release syndrome observed in 50% of mosunetuzumab patients
  • Best overall response rate in mosunetuzumab cohort was 67%

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d58ehttps://doi.org/10.1182/blood-2025-1952
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis2025 · 5 citations
  2. 2Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma2025
  3. 3Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma2024 · 6 citations
  4. 4Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma2025
  5. 5Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations